Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use

Weber, Wolfgang; Petersen, Volker; Schmidt, Burkhard; Tyndale-Hines, Leishia; Link, Thomas M.; Peschel, Christian; Schwaiger, Markus

doi:10.1200/jco.2003.12.004

Cited by 458 publications

(319 citation statements)

References 29 publications

Supporting

Mentioning

297

Contrasting

Unclassified

Order By: Relevance

“…In many studies, early metabolic changes measurable by [

^{18} normalF

]FDG‐PET were highly predictive of clinical responses observed weeks to months later. Such findings have been reported for a variety of cancers, including lymphoma, as well as breast, esophageal, gastric, colorectal, head and neck, and non‐small‐cell lung cancers 5 , 16 . Early declines in [

^{18} normalF

]FDG uptake generally correlate with longer progression‐free and overall survival.…”

Section: Introductionsupporting

confidence: 65%

“…Although [

^{18} normalF

]FDG‐PET is commonly employed for monitoring responses to chemotherapy, 8 , 9 , 15 , 16 it has been less utilized in monitoring effects following irradiation. While the exact mechanisms and extent of metabolic responses in healthy tissues have not yet been well defined, interpretation of [

^{18} normalF

]FDG uptake can be substantially complicated by radiation‐induced inflammation and other effects occurring in surrounding tissues.…”

Section: Discussionmentioning

confidence: 99%

“…Early declines in [

^{18} normalF

]FDG uptake generally correlate with longer progression‐free and overall survival. The available data suggest that [

^{18} normalF

]FDG may be utilized for predicting treatment responses as early as one to three weeks after the first cycle of chemotherapy in a variety of cancer types 8 , 9 , 15 , 16 . This can prevent the exposure of patients to prolonged, ineffective treatments with undesirable side effects.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Time‐course of effects of external beam radiation on [¹⁸F]FDG uptake in healthy tissue and bone marrow

Kesner

Lau

Speiser

et al. 2008

J Applied Clin Med Phys

View full text Add to dashboard Cite

The utility of PET for monitoring responses to radiation therapy have been complicated by metabolically active processes in surrounding normal tissues. We examined the time‐course of [18F]FDG uptake in normal tissues using small animal‐dedicated PET during the 2 month period following external beam radiation. Four mice received 12 Gy of external beam radiation, in a single fraction to the left half of the body. Small animal [18F]FDG‐PET scans were acquired for each mouse at 0 (pre‐radiation), 1, 2, 3, 4, 5, 8, 12, 19, 24, and 38 days following irradiation. [18F]FDG activity in various tissues was compared between irradiated and non‐irradiated body halves before, and at each time point after irradiation. Radiation had a significant impact on [18F]FDG uptake in previously healthy tissues, and time‐course of effects differed in different types of tissues. For example, liver tissue demonstrated increased uptake, particularly over days 3–12, with the mean left to right uptake ratio increasing 52% over mean baseline values false(normalp<0.0001false). In contrast, femoral bone marrow uptake demonstrated decreased uptake, particularly over days 2–8, with the mean left to right uptake ratio decreasing 26% below mean baseline values false(normalp=0.0005false). Significant effects were also seen in lung and brain tissue. Radiation had diverse effects on [18F]FDG uptake in previously healthy tissues. These kinds of data may help lay groundwork for a systematically acquired database of the time‐course of effects of radiation on healthy tissues, useful for animal models of cancer therapy imminently, as well as interspecies extrapolations pertinent to clinical application eventually.PACs Number: 87.50.‐a

show abstract

“…In many studies, early metabolic changes measurable by [

^{18} normalF

^{18} normalF

]FDG uptake generally correlate with longer progression‐free and overall survival.…”

Section: Introductionsupporting

confidence: 65%

“…Although [

^{18} normalF

^{18} normalF

]FDG uptake can be substantially complicated by radiation‐induced inflammation and other effects occurring in surrounding tissues.…”

Section: Discussionmentioning

confidence: 99%

“…Early declines in [

^{18} normalF

]FDG uptake generally correlate with longer progression‐free and overall survival. The available data suggest that [

^{18} normalF

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Time‐course of effects of external beam radiation on [¹⁸F]FDG uptake in healthy tissue and bone marrow

Kesner

Lau

Speiser

et al. 2008

J Applied Clin Med Phys

View full text Add to dashboard Cite

show abstract

“…19,20 Weber and colleagues found that the sensitivity for differentiating residual tumor from complete pathologic response was 67%. 21 These findings were supported by similar work by Cerfolio and colleagues, who showed that the change in tumor FDG uptake measured as SUV had a linear relationship with percent nonviable tumor cells in resected tumor specimens. 19 These data also correlate with patient outcome.…”

Section: Lung Cancersupporting

confidence: 70%

PET Imaging for Treatment Response in Cancer

Eary

2008

PET Clinics

View full text Add to dashboard Cite

KeywordsPET; FDG; Cancer imaging; Response imaging PET tumor surveys have become widely used in clinical practice. [F-18] fluorodeoxyglucose (FDG) is the most commonly used radiotracer for clinical indication of tumor staging and restaging after treatment. FDG PET consistently has exhibited better diagnostic performance than conventional imaging in adults and pediatric populations. [1][2][3][4] More recently, a growing body of literature is reporting the use of FDG and other PET imaging agents in treatment response assessment. [5][6][7] In many cases, FDG PET has proved to be a reliable means of noninvasively observing response in various treatments.Additionally, reliable determination of past treatment changes, including recurrent tumors and differentiation of benign and malignant lesions, will reduce morbidity and the cost of care in anatomic imaging. The Response Evaluation Criteria in Solid Tumors (RECIST) are a useful means to report quantitative changes in tumor size on CT scans in many different tumors in response to treatment. 8,9,10 Many tumor types, however, do not change size appreciably in response to treatment. Early changes that may indicate treatment regimen effectiveness also may not result in tumor change in size. FDG PET is a relatively sensitive indicator of treatment response in many tumors, indicating changes in metabolism that often precede or take the place of tumor size change. Fig. 1 shows some examples of FDG PET tumor response.Recently, several cooperative groups have addressed the use of FDG PET as a biomarker for cancer treatment response. An early report by the European Organization for Research and Treatment of Cancer (EORTC) set criteria for treatment response according to changes in tumor FDG uptake compared to baseline. 2 These criteria include:Complete response (CR)- [F-18] fluorodeoxyglucose uptake is comparable to baseline activity in all lesions Partial response (PR)-all target lesions have greater than 25% decrease in standardized uptake variable (SUV) Stable disease (SD)-target lesions have less than 25% increase or decrease in SUV Progressive disease (PD)-at least one target lesion has greater than 25% increase in SUV, or new lesions appear (regardless of SUV changes in target lesions)These criteria are in wide use today for clinical FDG PET imaging. A set of criteria for clinically significant changes in tumor FDG uptake, however, is based on consistent parameters for the FDG PET acquisition between studies in the same patient, and between patient imaging groups at different institutions. Development and evaluation of new cancer therapies could be enhanced by a set of validated biomarkers for treatment response. FDG PET meets these criteria in clinical studies, if imaging studies are conducted with patients on clinical therapeutic trials in a reliable and consistent manner. 3 To address the consistency in FDG PET data for use as NIH Public Access A review of cancer treatment response begins with consideration of the pathological basis of the tumor process. Tumors are c...

show abstract

“…The potential of FDG-PET/CT for staging in patients with diagnosed NSCLC has been demonstrated [2,23]. Based on SUV changes, 18 F-FDG uptake can determine patient prognoses after treatment [24,25] and predict tumor response [26]. On the other hand, DWI also has an established role in tumor detection [11] and response assessment.…”

mentioning

confidence: 99%

Correlation of the Apparent Diffusion Coefficient (ADC) with the Standardized Uptake Value (SUV) in Hybrid 18F-FDG PET/MRI in Non-Small Cell Lung Cancer (NSCLC) Lesions: Initial Results

Heusch¹,

Buchbender²,

Köhler

et al. 2013

Fortschr Röntgenstr

View full text Add to dashboard Cite

Purpose: To compare the apparent diffusion coefficient (ADC) in non-small cell lung cancer lesions with standardized uptake values (SUV) derived from combined 18F-fluoro-deoxy-glucose-positron emission tomography/magnetic resonance imaging (FDG-PET/MRI) and those derived from FDG-PET/CT. Materials and Methods: In 18 consecutive patients with histologically proven NSCLC (17 men, 1 woman; mean age, 61???12 years), whole-body FDG-PET/MRI was performed after whole-body FDG-PET/CT. Regions of interest (ROI) encompassing the entire primary tumor were drawn into FDG-PET/CT and FDG-PET/MR images to determine the maximum and mean standardized uptake value (SUVmax; SUVmean) and into ADC parameter maps to assess mean ADC values. Pearson?s correlation coefficients were calculated to compare SUV and ADC values. Results: The SUVmax of NSCLC was 12.3???4.8 [mean ?SD], and the SUVmean was 7.2???2.8 as assessed by FDG-PET/MRI. The SUVmax and SUVmean derived from FDG-PET/CT and FDG-PET/MRI correlated well (R?=?0.93; p?

show abstract

Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use

Cited by 458 publications

References 29 publications

Time‐course of effects of external beam radiation on [¹⁸F]FDG uptake in healthy tissue and bone marrow

Time‐course of effects of external beam radiation on [¹⁸F]FDG uptake in healthy tissue and bone marrow

PET Imaging for Treatment Response in Cancer

Correlation of the Apparent Diffusion Coefficient (ADC) with the Standardized Uptake Value (SUV) in Hybrid 18F-FDG PET/MRI in Non-Small Cell Lung Cancer (NSCLC) Lesions: Initial Results

Contact Info

Product

Resources

About

Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use

Cited by 458 publications

References 29 publications

Time‐course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow

Time‐course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow

PET Imaging for Treatment Response in Cancer

Correlation of the Apparent Diffusion Coefficient (ADC) with the Standardized Uptake Value (SUV) in Hybrid 18F-FDG PET/MRI in Non-Small Cell Lung Cancer (NSCLC) Lesions: Initial Results

Contact Info

Product

Resources

About

Time‐course of effects of external beam radiation on [¹⁸F]FDG uptake in healthy tissue and bone marrow

Time‐course of effects of external beam radiation on [¹⁸F]FDG uptake in healthy tissue and bone marrow